![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/04\/03868ae05a8c0d3309f82934183c8011.jpeg\")
<\/p>\n <\/p>\n
Novo Nordisk A\/S on Tuesday introduced a multi-month subscription program for its obesity treatment Wegovy (semaglutide), aiming to make pricing more predictable for self-pay patients and improve long-term adherence.<\/p>\n
Earlier in March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an expansion of its treatment portfolio for adults with obesity.<\/p>\n
The newly approved Wegovy HD (semaglutide) injection 7.2 mg is for patients who have already tolerated the currently approved 2.4 mg dose and require additional weight reduction.<\/p>\n
Don’t Miss:<\/p>\n
The program, available starting March 31, 2026, allows eligible patients to access FDA-approved treatment through select telehealth providers at a fixed monthly cost.<\/p>\n
Novo Nordisk outlined a tiered pricing structure based on subscription duration, with longer commitments offering lower monthly costs.<\/p>\n
For Wegovy injections, monthly pricing ranges from $329 under a three-month plan to $249 under a 12-month plan, translating into annual savings of up to $1,200.<\/p>\n
The oral version is priced between $289 and $249 per month, with potential savings of up to $600 annually.<\/p>\n
Trending:\u00a0Most Retirement Plans Ignore Taxes \u2014 See If Yours Does<\/a><\/p>\n Additional lower-dose options are available at reduced rates, with certain promotional pricing set to expire later in 2026.<\/p>\n The company noted that limited-time offers are separate from subscription pricing and may vary by platform.<\/p>\n The subscription program will initially be offered through telehealth providers, including Ro, WeightWatchers, and LifeMD Inc, with platforms such as Hims & Hers Health Inc. and Sesame expected to join later.<\/p>\n Novo Nordisk said patients should contact providers directly for eligibility and enrollment details, as terms may differ across platforms.<\/p>\n The company emphasized that obesity requires ongoing management under medical supervision, positioning the subscription model as a way to encourage treatment continuity.<\/p>\n See Also:\u00a0This Startup Thinks It Can Reinvent the Wheel \u2014 Literally<\/a><\/p>\n Beyond telehealth, Wegovy remains available through more than 70,000 U.S. pharmacies and NovoCare Pharmacy.<\/p>\n Patients with commercial insurance may access the drug for as little as $25 per month through existing savings programs.<\/p>\n Last week, at least six Indian pharmaceutical companies introduced generic versions of Novo Nordisk\u2019s Ozempic and Wegovy<\/a>.<\/p>\n Following the expiration of the Indian patent for semaglutide last week, these manufacturers are offering treatments at globally unmatched prices, effectively reducing costs by approximately 70%.<\/p>\n Read Next:\u00a0See What AI Could Build for Your Portfolio \u2014 Try a Custom Index Now<\/a><\/p>\n Image via Shutterstock<\/p>\n Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights<\/a> that can set you ahead in today’s competitive market.<\/p>\n Get the latest stock analysis from Benzinga:<\/p>\n This article Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan<\/a> originally appeared on Benzinga.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S on Tuesday introduced a multi-month subscription program for its obesity treatment Wegovy (semaglutide), aiming to…\n","protected":false},"author":2,"featured_media":54448,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[272,29194],"class_list":{"0":"post-54447","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-novo-nordisk","9":"tag-subscription-program"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116338242757785205","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=54447"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/54447\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/54448"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=54447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=54447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=54447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}